Diabetes hardware company embecta aims to look beyond insulin and reshape itself into a more varied drug delivery provider—and it’s kick-starting that effort with the acquisition of a glo | Embecta ...

Embecta hits multi-year lows on GLP-1 fears, but offers 6%+ yield and deep value. Read the latest analysis on the stock and ...

Your Ozempic is set to get cheaper. But with over 50 brands of the same molecule hitting the market this year, which one will ...

ILLEGAL fake weight loss jabs are now being sold in pubs and fish and chip shops, a concerning report has revealed. The ...

With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.

Lupin and Zydus partner to co-market semaglutide in India, entering a Rs 1,200 crore market with over 20 competitors and rapidly commoditising pricing dynamics.

The investigation, published by the London Assembly health committee, said it had also found evidence of personal trainers ...

Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.

Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely ...

“Insulin injections remain a daily burden for many patients,” said Associate Professor Shingo Ito. “Our peptide-based ...

A workplace text over a routine medical act raises sharp questions about privacy, disability rights and who must adapt.

About 10 weeks after it was approved, the Wegovy pill is now estimated to be part of the daily regimen of about 400,000 Americans. And the field of weight-loss treatment is on the verge of even more ...